At the 2023 ASCO annual meeting, Carolina Schinke, MD, discussed updated results from the MonumenTAL-1 trial which indicated that patients with heavily pretreated R/R multiple myeloma had impressive responses to treatment with talquetamab.
At the 2023 ASCO annual meeting, Carolina Schinke, MD, discussed updated results from the MonumenTAL-1 trial which indicated that patients with heavily pretreated R/R multiple myeloma had impressive responses to treatment with talquetamab.
At the 2023 ASCO annual meeting,...